GLOBAL HEALTH | GLOBAL PARTNERSHIPS | GLOBAL IMPACT

Research

Photo for The International Polycap Study (TIPS)-3

The International Polycap Study (TIPS)-3

Official Title

A randomized double-blind placebo-controlled trial for the evaluation of a polypill (with and without aspirin) and vitamin D supplementation in a primary prevention setting to reduce cardiovascular disease (CVD) outcomes – The International Polycap Study 3

Status

Ongoing

Overview

To evaluate a polypill (with and without aspirin) and vitamin D supplementation in a primary prevention setting to reduce cardiovascular disease (CVD) outcomes

Study Design

Randomized, double-blind, 2x2x2 factorial, placebo controlled trial determining the effect of double strength Polycap™ , aspirin, and vitamin D compared to their respective placebos.

Number of Patients

5000

Number of Sites

80

Study Period

2012–TBA

Principal Investigator

Salim Yusuf, Koon Teo

Program Manager

Jackie Bosch

Research Coordinator

Jessica Tyrwhitt

Key Publications

  • Philip J, Pais P, Dans, A, Bosch J, Xavier D, Lopez-Jaramillo P, Yusoff K, Santoso A, Talukder S, Gamra H, Yeates K, Camacho Lopez P, Tyrwhitt J, Gao P, Teo K, Yusuf S on behalf of the TIPS-3 Investigators. The International Polycap Study-3 (TIPS-3): Design, baseline characteristics and challenges in conduct. Am Heart J. 2018 Dec;206:72-79. doi: 10.1016/j.ahj.2018.07.012. Epub 2018 Aug 2.
  • Lonn E, Bosch J, Teo KK, et al. The Polypill in the Prevention of Cardiovascular Diseases: Key Concepts, Current Status, Challenges, and Future Directions. Circulation. 2010; 122: 2078-2088.
  • Smith R, McCready T, Yusuf S. Combination therapy to prevent cardiovascular disease: slow progress. JAMA. Apr 17 2013;309(15):1595-1596.
  • Writing Group on the Summit on Combination Therapy for CVD (Yusuf S, Ataran A, Bosch J, Joseph P, Lonn E, McCready T, Mente A, Nieuwlaat R, Pais P, Rodgers A, Schwalm J-D, Smith R, Teo K, Xavier D). Combination Pharmacotherapy to Prevent CVD: Present Status and Challenges. Eur Heart J. 2013 (Nov) doi:10.1093/Eurheartj/eht407.